AstraZeneca PLC

NYSE:AZN

Drug Manufacturers - General

Healthcare
$178.76 -1.71%

-$3.04 today

Market cap
$277.23B
Beta
0.21
P/E (TTM)
25.7
EPS (TTM)
$6.75
Dividend yield
1.80%
52W Low $137.22High $212.71

Volume 2.54M

Average 1.96M

AZN Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

AstraZeneca PLCNYSE: AZN

Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q3 FY2026 depreciation & amortization of $1.58B rose 2.2% year over year, behind the +29.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 17.9% from the prior quarter. Over 3 fiscal years it compounded at +3.0% a year.

Context

  • Depreciation & amortization amounted to 9.8% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +2.2% toward the trailing-twelve-month pace of +29.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$1.58B-17.9% QoQ
Last fiscal yearDec 2025
$5.73B+13.2% YoY
LTMSep 2026
$6.41B+29.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.2%——
1 year+13.2%——
3-year CAGR+3.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
5.73B USD
Year-over-year change
+13.2%
4-year CAGR
+8.7%

Depreciation & Amortization vs competitors

How AZN compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +29.8% is the 3rd highest of 10, against a peer median of -3.0%.
  • Depreciation & amortization amounts to 10.3% of revenue for AZN, versus a peer median of 9.6%.
AZN Competitors
Depreciation & Amortization for AZN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 27.16B DKK+69.6%+44.0%8.2%
JNJJohnson & JohnsonLTM Sep 2026$8.09B USD+9.5%+2.5%8.1%
ABBVAbbVie Inc.LTM Jun 2026$7.87B USD-4.8%-1.3%12.2%
MRKMerck & Co., Inc.LTM Jun 2026$6.72B USD+45.9%+14.3%10.1%
PFEPfizer Inc.LTM Jun 2026$6.58B USD-3.0%+9.2%10.3%
AZNAstraZeneca PLCLTM Sep 2026$6.41B USD+29.8%+3.0%10.3%
NVSNovartis AGLTM Jun 2026$5.34B USD-11.0%-7.2%9.6%
AMGNAmgen Inc.LTM Jun 2026$4.67B USD-15.5%+14.8%12.2%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$3.18B USD-51.1%-26.9%6.5%
LLYEli Lilly and CompanyLTM Jun 2026$2.1B USD+10.9%+9.5%2.6%
Peer median (excluding AZN) —-3.0%+9.2%9.6%

Competitors are the stored peer set for AZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(265M)2.5B6.9B8.69B10.23B
Depreciation & Amortization4.1B5.25B4.93B5.07B5.73B
Deferred Income Tax(615M)(619M)000
Stock-Based Compensation615M619M579M00
Change in Working Capital2.02B3.76B300M(893M)(1.16B)
Accounts Receivables(961M)(1.35B)(1.43B)(1.62B)0
Inventory1.58B3.94B(669M)(131M)0
Accounts Payables961M1.35B1.43B00
Other Working Capital444M(184M)969M862M(1.16B)
Other Non-Cash Items105M(1.7B)(2.37B)(1B)(220.71M)
Operating Cash Flow5.96B9.81B10.35B11.86B14.58B
Capital Expenditures(2.2B)(2.57B)(3.78B)(4.59B)(5.91B)
Acquisitions (Net)(9.43B)(1.06B)(1.18B)(3.93B)(1.24B)
Purchases of Investments(184M)(159M)(136M)(96M)(229M)
Sales of Investments105M42M129M108M131M
Other Investing Activities654M789M(1.52B)(2.14B)(2.66B)
Investing Cash Flow(11.06B)(2.96B)(4.06B)(7.98B)(6.81B)
Debt Repayment7.89B(1.2B)(965M)1.81B(1.65B)
Common Stock Issued29M29M33M(43M)(481M)
Common Stock Repurchased00000
Dividends Paid(3.86B)(4.36B)(4.48B)(4.63B)(4.97B)
Other Financing Activities(418M)(1.29B)(1.15B)(1.13B)(442M)
Financing Cash Flow3.65B(6.82B)(6.57B)(4B)(7.54B)
Effect of Forex Changes(62M)(80M)(60M)(93M)46M
Net Change in Cash(1.51B)(55M)(346M)(208M)269M
Free Cash Flow3.76B7.24B6.57B7.28B8.67B

AstraZeneca PLC

NYSE:AZN

Intrinsic Alpha fair value

Locked

Current Price

$178.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.